Milestone Pharmaceuticals Announces $25 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Milestone Pharmaceuticals (MIST) PT Doubled to $12 at Cowen
July 23, 2020 3:43 PM EDTCowen analyst Ritu Baral raised the price target on Milestone Pharmaceuticals (NASDAQ: MIST) to $12.00 (from $6.00) while maintaining an Outperform rating.
The analyst commented, "MIST announced etrepamil's path forward agreed upon with FDA which allows amending the NODE-301 trial stat plan for... More
Milestone Pharmaceuticals Inc. (MIST) Surges 70% on Updated Clinical Development Plan for Etripamil in PSVT
July 23, 2020 8:06 AM EDTMilestone Pharmaceuticals Inc. (NASDAQ: MIST) surges 70% after the company announced a clinical and regulatory update... More
Milestone Pharmaceuticals Inc. (MIST) Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
July 23, 2020 7:15 AM EDTMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced a clinical and regulatory update for its pivotal program with etripamil following recent interactions with the U.S. Food and Drug Administration (FDA). Etripamil nasal spray is the Company's investigational novel short-acting calcium channel blocker for patients with paroxysmal supraventricular tachycardia (PSVT).
"We are pleased with the outcome of our recent interactions with the FDA, as they outline an efficient path to registration for etripamil which eliminates the need to start a... More
